companies innovating in obesity treatment glp-1 drugs 2025 GLP-1s and Coverage: Differing Perspectives for Employers and Health Plans SUSTAINABLE GLP-1 DRUG DELIVERY: FUTURE-PROOFING

Tirzepatide suppresses palatable food intake by selectively reducing preference for fat in rodents In collaboration with Eli Lilly, we showed that the dual GLP-1/GIP agonist Tirzepatide robustly decreases preference for palatable foods by selectively decreasing lipid consumption

A GI-MAP reveals whether youre dealing with infections, candida, parasites, enzyme insufficiency, or inflammation information that determines which peptides to use, at what doses, and what other interventions need to happen simultaneously

Elevated oxidative stress and subsequent mitochondrial dysfunction are associated with biological aging

Suitable for regenerative and anti-aging research models